Nanomedicines for cancer therapy: State-of-the-art and limitations to pre-clinical studies that hinder future developments

Frontiers in Chemistry

Volumn 2, Issue AUG, 2014, Pages

  Dawidczyk, Charlene M ^a,b   Russell, Luisa M ^a,b   Searson, Peter C ^a,b  

^a Whiting School of Engineering   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Drug delivery systems; Nanoparticles; Pharmacokinetics; Targeted therapy; Tumor accumulation

Indexed keywords

EID: 84987602369     PISSN: None     EISSN: 22962646     Source Type: Journal    
DOI: 10.3389/fchem.2014.00069     Document Type: Review

References (180)

1. Adamis, A. P., Altaweel, M., Bressler, N. M., Cunningham, E. T., Davis, M. D., Goldbaum, M., et al. (2006). Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 113, 23-28. doi: 10.1016/j.ophtha.2005.10.012
2. Allen, T. M. (2002). Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer 2, 750-763. doi: 10.1038/nrc903
3. Ando, M., Yonemori, K., Katsumata, N., Shimizu, C., Hirata, T., Yamamoto, H., et al. (2012). Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer. Cancer Chemother. Pharmacol. 69, 457-465. doi: 10.1007/s00280-011-1726-5
4. Arruebo, M., Fernández-Pacheco, R., Ibarra, M. R., and Santamaría, J. (2007). Magnetic nanoparticles for drug delivery. Nano Today 2, 22-32. doi: 10.1016/S1748-0132(07)70084-1
5. Arruebo, M., Valladares, M., and Gonzalez-Fernandez, A. (2009). Antibody-conjugated nanoparticles for biomedical applications. J. Nanomat. 2009:439389. doi: 10.1155/2009/439389
6. Arvizo, R., Bhattacharya, R., and Mukherjee, P. (2010). Gold nanoparticles: opportunities and challenges in nanomedicine. Expert Opin. Drug Deliv. 7, 753-763. doi: 10.1517/17425241003777010
7. Balogh, L., Nigavekar, S. S., Nair, B. M., Lesniak, W., Zhang, C., Sung, L. Y., et al. (2007). Significant effect of size on the in vivo biodistribution of gold composite nanodevices in mouse tumor models. Nanomed. Nanotechnol. Biol. Med. 3, 281-296. doi: 10.1016/j.nano.2007.09.001
8. Banerjee, R., Katsenovich, Y., Lagos, L., McIintosh, M., Zhang, X., and Li, C. Z. (2010). Nanomedicine: magnetic nanoparticles and their biomedical applications. Curr. Med. Chem. 17, 3120-3141. doi: 10.2174/092986710791959765
9. Banerjee, S. R., Foss, C. A., Castanares, M., Mease, R. C., Byun, Y., Fox, J. J., et al. (2008). Synthesis and evaluation of technetium-99m-and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J. Med. Chem. 51, 4504-4517. doi: 10.1021/jm800111u
10. Barenholz, Y. (2012). Doxil(R)-the first FDA-approved nano-drug: lessons learned. J. Control. Release 160, 117-134. doi: 10.1016/j.jconrel.2012.03.020
11. Bedikian, A. Y., Silverman, J. A., Papadopoulos, N. E., Kim, K. B., Hagey, A. E., Vardeleon, A., et al. (2011). Pharmacokinetics and safety of marqibo (vincristine sulfate liposomes injection) in cancer patients with impaired liver function. J. Clin. Pharmacol. 51, 1205-1212. doi: 10.1177/0091270010381499
12. Bellott, R., Auvrignon, A., Leblanc, T., Perel, Y., Gandemer, V., Bertrand, Y., et al. (2001). Pharmacokinetics of liposomal daunorubicin [DaunoXome] during a phase I-II study in children with relapsed acute lymphoblastic leukaemia. Cancer Chemother. Pharmacol. 47, 15-21. doi: 10.1007/s002800000206
13. Benezra, M., Penate-Medina, O., Zanzonico, P. B., Schaer, D., Ow, H., Burns, A., et al. (2011). Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. J. Clin. Invest. 121, 2768-2780. doi: 10.1172/JCI45600
14. Blanco, E., Bey, E. A., Khemtong, C., Yang, S. G., Setti-Guthi, J., Chen, H. B., et al. (2010). Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy. Cancer Res. 70, 3896-3904. doi: 10.1158/0008-5472.CAN-09-3995
15. Boisselier, E., and Astruc, D. (2009). Gold nanoparticles in nanomedicine: preparations, imaging, diagnostics, therapies and toxicity. Chem. Soc. Rev. 38, 1759-1782. doi: 10.1039/b806051g
16. Bradley, A. M., Devine, M., and Deremer, D. (2013). Brentuximab vedotin: an anti-CD30 antibody-drug conjugate. Am. J. Health Syst. Pharm. 70, 589-597. doi: 10.2146/ajhp110608
17. Bunka, D. H. J., and Stockley, P. G. (2006). Aptamers come of age-at last. Nat. Rev. Microbiol. 4, 588-596. doi: 10.1038/nrmicro1458
18. Burns, A., Ow, H., and Wiesner, U. (2006). Fluorescent core-shell silica nanoparticles: towards "Lab on a Particle" architectures for nanobiotechnology. Chem. Soc. Rev. 35, 1028-1042. doi: 10.1039/b600562b
19. Chames, P., Van Regenmortel, M., Weiss, E., and Baty, D. (2009). Therapeutic antibodies: successes, limitations and hopes for the future. Br. J. Pharmacol. 157, 220-233. doi: 10.1111/j.1476-5381.2009.00190.x
20. Chanda, N., Kattumuri, V., Shukla, R., Zambre, A., Katti, K., Upendran, A., et al. (2010). Bombesin functionalized gold nanoparticles show in vitro and in vivo cancer receptor specificity. Proc. Natl. Acad. Sci. U.S.A. 107, 8760-8765. doi: 10.1073/pnas.1002143107
21. Chattopadhyay, N., Fonge, H., Cai, Z., Scollard, D., Lechtman, E., Done, S. J., et al. (2012). Role of antibody-mediated tumor targeting and route of administration in nanoparticle tumor accumulation in vivo. Mol. Pharm. 9, 2168-2179. doi: 10.1021/mp300016p
22. Chen, F., Hong, H., Zhang, Y., Valdovinos, H. F., Shi, S. X., Kwon, G. S., et al. (2013). In vivo tumor targeting and image-guided drug delivery with antibody-conjugated, radio labeled mesoporous silica nanoparticles. ACS Nano 7, 9027-9039. doi: 10.1021/nn403617j
23. Chen, L. C., Wu, Y. H., Liu, I. H., Ho, C. L., Lee, W. C., Chang, C. H., et al. (2012a). Pharmacokinetics, dosimetry and comparative efficacy of Re-188-liposome and 5-FU in a CT26-luc lung-metastatic mice model. Nucl. Med. Biol. 39, 35-43. doi: 10.1016/j.nucmedbio.2011.06.010
24. Chen, M., Fang, X. L., Tang, S. H., and Zheng, N. F. (2012b). Polypyrrole nanoparticles for high-performance in vivo near-infrared photothermal cancer therapy. Chem. Commun. 48, 8934-8936. doi: 10.1039/c2cc34463g
25. Cheng, K., Kothapalli, S. R., Liu, H. G., Koh, A. L., Jokerst, J. V., Jiang, H., et al. (2014). Construction and validation of nano gold tripods for molecular imaging of living subjects. J. Am. Chem. Soc. 136, 3560-3571. doi: 10.1021/ja412001e
26. Cho, K., Wang, X., Nie, S., Chen, Z. G., and Shin, D. M. (2008). Therapeutic nanoparticles for drug delivery in cancer. Clin. Cancer Res. 14, 1310-1316. doi: 10.1158/1078-0432.CCR-07-1441
27. Choi, C. H. J., Alabi, C. A., Webster, P., and Davis, M. E. (2010). Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc. Natl. Acad. Sci. U.S.A. 107, 1235-1240. doi: 10.1073/pnas.0914140107
28. Coimbra, M., Rijcken, C. J. F., Stigter, M., Hennink, W. E., Storm, G., and Schiffelers, R. M. (2012). Antitumor efficacy of dexamethasone-loaded core-crosslinked polymeric micelles. J. Control. Release 163, 361-367. doi: 10.1016/j.jconrel.2012.09.014
29. Cornelissen, B., Able, S., Kersemans, V., Waghorn, P. A., Myhra, S., Jurkshat, K., et al. (2013). Nanographene oxide-based radioimmunoconstructs for in vivo targeting and SPECT imaging of HER2-positive tumors. Biomaterials 34, 1146-1154. doi: 10.1016/j.biomaterials.2012.10.054
30. Daniels, T. R., Bernabeu, E., Rodriguez, J. A., Patel, S., Kozman, M., Chiappetta, D. A., et al. (2012). The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim. Biophys. Acta 1820, 291-317. doi: 10.1016/j.bbagen.2011.07.016
31. Davis, M. E., Chen, Z., and Shin, D. M. (2008). Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 7, 771-782. doi: 10.1038/nrd2614
32. Dawidczyk, C. M., Kim, C., Park, J. H., Russell, L. M., Lee, K. H., Pomper, M. G., et al. (2014). State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines. J. Control. Release 187, 133-144. doi: 10.1016/j.jconrel.2014.05.036
33. Dechantsreiter, M. A., Planker, E., Matha, B., Lohof, E., Holzemann, G., Jonczyk, A., et al. (1999). N-methylated cyclic RGD peptides as highly active and selective alpha(v)beta(3) integrin antagonists. J. Med. Chem. 42, 3033-3040. doi: 10.1021/jm970832g
34. Dill, K., Lin, M., Poteras, C., Fraser, C., Hafeman, D. G., Owicki, J. C., et al. (1994). Antibody-antigen binding constants determined in solution-phase with the threshold membrane-capture system-binding constants for antifluorescein, anti-saxitoxin, and anti-ricin antibodies. Anal. Biochem. 217, 128-138. doi: 10.1006/abio.1994.1093
35. Di Pasqua, A. J., Miller, M. L., Lu, X. L., Peng, L., and Jay, M. (2012). Tumor accumulation of neutron-activatable holmium-containing mesoporous silica nanoparticles in an orthotopic non-small cell lung cancer mouse model. Inorganica Chim. Acta 393, 334-336. doi: 10.1016/j.ica.2012.06.016
36. Duncan, R. (2006). Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer 6, 688-701. doi: 10.1038/nrc1958
37. Erttmann, R., Erb, N., Steinhoff, A., and Landbeck, G. (1988). Pharmacokinetics of doxorubicin in man: dose and schedule dependence. J. Cancer Res. Clin. Oncol. 114, 509-513. doi: 10.1007/BF00391502
38. Fang, J., Nakamura, H., and Maeda, H. (2011). The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev. 63, 136-151. doi: 10.1016/j.addr.2010.04.009
39. Fonge, H., Huang, H., Scollard, D., Reilly, R. M., and Allen, C. (2012). Influence of formulation variables on the biodistribution of multifunctional block copolymer micelles. J. Control. Release 157, 366-374. doi: 10.1016/j.jconrel.2011.09.088
40. Frese, K. K., and Tuveson, D. A. (2007). Maximizing mouse cancer models. Nat. Rev. Cancer 7, 645-658. doi: 10.1038/nrc2192
41. Fuchs, S., and Coester, C. (2010). Protein-based nanoparticles as a drug delivery system: chances, risks, perspectives. J. Drug Deliv. Sci. Technol. 20, 331-342.
42. Furger, K. A., Allan, A. L., Wilson, S. M., Hota, C., Vantyghem, S. A., Postenka, C. O., et al. (2003). Beta(3) integrin expression increases breast carcinoma cell responsiveness to the malignancy-enhancing effects of osteopontin. Mol. Cancer Res. 1, 810-819.
43. Gabizon, A., Catane, R., Uziely, B., Kaufman, B., Safra, T., Cohen, R., et al. (1994). Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 54, 987-992.
44. Gabizon, A., Shmeeda, H., and Barenholz, Y. (2003). Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin. Pharmacokinet. 42, 419-436. doi: 10.2165/00003088-200342050-00002
45. Gao, J. H., Chen, K., Xie, R. G., Xie, J., Yan, Y. J., Cheng, Z., et al. (2010). In vivo tumor-targeted fluorescence imaging using near-infrared non-cadmium quantum dots. Bioconjug. Chem. 21, 604-609. doi: 10.1021/bc900323v
46. Gao, X. H., Cui, Y. Y., Levenson, R. M., Chung, L. W. K., and Nie, S. M. (2004). In vivo cancer targeting and imaging with semiconductor quantum dots. Nat. Biotechnol. 22, 969-976. doi: 10.1038/nbt994
47. Gill, P. S., Wernz, J., Scadden, D. T., Cohen, P., Mukwaya, G. M., Von Roenn, J. H., et al. (1996). Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J. Clin. Oncol. 14, 2353-2364.
48. Giri, S., Trewyn, B. G., and Lin, V. S. Y. (2007). Mesoporous silica nanomaterial-based biotechnological and biomedical delivery systems. Nanomedicine 2, 99-111. doi: 10.2217/17435889.2.1.99
49. Giri, S., Trewyn, B. G., Stellmaker, M. P., and Lin, V. S. (2005). Stimuli-responsive controlled-release delivery system based on mesoporous silica nanorods capped with magnetic nanoparticles. Angew. Chem. Int. Ed. Engl. 44, 5038-5044. doi: 10.1002/anie.200501819
50. Girish, S., Gupta, M., Wang, B., Lu, D., Krop, I. E., Vogel, C. L., et al. (2012). Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother. Pharmacol. 69, 1229-1240. doi: 10.1007/s00280-011-1817-3
51. Greco, F., and Vicent, M. J. (2009). Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Adv. Drug Deliv. Rev. 61, 1203-1213. doi: 10.1016/j.addr.2009.05.006
52. Hainfeld, J. F., Slatkin, D. N., Focella, T. M., and Smilowitz, H. M. (2006). Gold nanoparticles: a new X-ray contrast agent. Br. J. Radiol. 79, 248-253. doi: 10.1259/bjr/13169882
53. Hamilton, A., Biganzoli, L., Coleman, R., Mauriac, L., Hennebert, P., Awada, A., et al. (2002). EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European organization for research and treatment of cancer. Ann. Oncol. 13, 910-918. doi: 10.1093/annonc/mdf157
54. Hanahan, D., and Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646-674. doi: 10.1016/j.cell.2011.02.013
55. Harrington, K. J., Rowlinson-Busza, G., Syrigos, K. N., Abra, R. M., Uster, P. S., Peters, A. M., et al. (2000). Influence of tumour size on uptake of In-111-DTPA-labelled pegylated liposomes in a human tumour xenograft model. Br. J. Cancer 83, 684-688. doi: 10.1054/bjoc.2000.1320
56. Hartmann, L. C., Keeney, G. L., Lingle, W. L., Christianson, T. J. H., Varghese, B., Hillman, D., et al. (2007). Folate receptor overexpression is associated with poor outcome in breast cancer. Int. J. Cancer 121, 938-942. doi: 10.1002/ijc.22811
57. Haubner, R., Gratias, R., Diefenbach, B., Goodman, S. L., Jonczyk, A., and Kessler, H. (1996). Structural and functional aspects of RGD-containing cyclic pentapeptides as highly potent and selective integrin alpha(v)beta(3) antagonists. J. Am. Chem. Soc. 118, 7461-7472. doi: 10.1021/ja9603721
58. Haun, J. B., Yoon, T. J., Lee, H., and Weissleder, R. (2010). Magnetic nanoparticle biosensors. Wiley Interdiscip. Rev. Nanome. Nanobiotechnol. 2, 291-304. doi: 10.1002/wnan.84
59. Helbok, A., Rangger, C., Von Guggenberg, E., Saba-Lepek, M., Radolf, T., Thurner, G., et al. (2012). Targeting properties of peptide-modified radiolabeled liposomal nanoparticles. Nanomedicine 8, 112-118. doi: 10.1016/j.nano.2011.04.012
60. Hilgenbrink, A. R., and Low, P. S. (2005). Folate receptor-mediated drug targeting: from therapeutics to diagnostics. J. Pharm. Sci. 94, 2135-2146. doi: 10.1002/jps.20457
61. Hoang, B., Lee, H., Reilly, R. M., and Allen, C. (2009). Noninvasive monitoring of the fate of in-111-labeled block copolymer micelles by high resolution and high sensitivity MicroSPECT/CT imaging. Mol. Pharm. 6, 581-592. doi: 10.1021/mp8002418
62. Holliger, P., and Hudson, P. J. (2005). Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 23, 1126-1136. doi: 10.1038/nbt1142
63. Hong, H., Yang, K., Zhang, Y., Engle, J. W., Feng, L., Yang, Y., et al. (2012). In vivo targeting and imaging of tumor vasculature with radiolabeled, antibody-conjugated nanographene. ACS Nano 6, 2361-2370. doi: 10.1021/nn204625e
64. Hong, R. L., and Tseng, Y. L. (2001). Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity. Cancer 91, 1826-1833. doi: 10.1002/1097-0142(20010501)91:9<1826::AID-CNCR1203>3.0.CO;2-J
65. Horcajada, P., Gref, R., Baati, T., Allan, P. K., Maurin, G., Couvreur, P., et al. (2012). Metal-organic frameworks in biomedicine. Chem. Rev. 112, 1232-1268. doi: 10.1021/cr200256v
66. Hosotani, R., Kawaguchi, M., Masui, T., Koshiba, T., Ida, J., Fujimoto, K., et al. (2002). Expression of integrin alphaVbeta3 in pancreatic carcinoma: relation to MMP-2 activation and lymph node metastasis. Pancreas 25, e30-e35. doi: 10.1097/00006676-200208000-00021
67. Hsu, C. W., Chang, Y. J., Chang, C. H., Chen, L. C., Lan, K. L., Ting, G., et al. (2012). Comparative therapeutic efficacy of rhenium-188 radiolabeled-liposome and 5-fluorouracil in LS-174T human colon carcinoma solid tumor xenografts. Cancer Biother. Radiopharm. 27, 481-489. doi: 10.1089/cbr.2011.1158
68. Hu, M., and Zhang, K. (2013). The application of aptamers in cancer research: an up-to-date review. Future Oncol. 9, 369-376. doi: 10.2217/fon.12.201
69. Hu, Z., Luo, F., Pan, Y., Hou, C., Ren, L., Chen, J., et al. (2008). Arg-Gly-Asp (RGD) peptide conjugated poly(lactic acid)-poly(ethylene oxide) micelle for targeted drug delivery. J. Biomed. Mater. Res. A 85, 797-807. doi: 10.1002/jbm.a.31615
70. Huang, F. Y. J., Lee, T. W., Kao, C. H. K., Chang, C. H., Zhang, X. N., Lee, W. Y., et al. (2011). Imaging, autoradiography, and biodistribution of Re-188-labeled PEGylated nanoliposome in orthotopic glioma bearing rat model. Cancer Biother. Radiopharm. 26, 717-725. doi: 10.1089/cbr.2011.1052
71. Hubert, A., Lyass, O., Pode, D., and Gabizon, A. (2000). Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer. Anticancer Drugs 11, 123-127. doi: 10.1097/00001813-200002000-00009
72. Huynh, N. T., Roger, E., Lautram, N., Benoit, J. P., and Passirani, C. (2010). The rise and rise of stealth nanocarriers for cancer therapy: passive versus active targeting. Nanomedicine (Lond). 5, 1415-1433. doi: 10.2217/nnm.10.113
73. Hynes, R. O. (2002). Integrins: bidirectional, allosteric signaling machines. Cell 110, 673-687. doi: 10.1016/S0092-8674(02)00971-6
74. Immordino, M. L., Dosio, F., and Cattel, L. (2006). Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int. J. Nanomedicine 1, 297-315.
75. Iyer, A. K., Su, Y., Feng, J., Lan, X., Zhu, X., Liu, Y., et al. (2011). The effect of internalizing human single chain antibody fragment on liposome targeting to epithelioid and sarcomatoid mesothelioma. Biomaterials 32, 2605-2613. doi: 10.1016/j.biomaterials.2010.11.073
76. Jacquet, J. M., Bressolle, F., Galtier, M., Bourrier, M., Donadio, D., Jourdan, J., et al. (1990). Doxorubicin and doxorubicinol: intra-and inter-individual variations of pharmacokinetic parameters. Cancer Chemother. Pharmacol. 27, 219-225. doi: 10.1007/BF00685716
77. Jain, K. K. (2012). Advances in use of functionalized carbon nanotubes for drug design and discovery. Expert Opin. Drug Discov. 7, 1029-1037. doi: 10.1517/17460441.2012.722078
78. Jain, R. K. (2005). Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58-62. doi: 10.1126/science.1104819
79. Jain, R. K., and Stylianopoulos, T. (2010). Delivering nanomedicine to solid tumors. Nat. Rev. Clin. Oncol. 7, 653-664. doi: 10.1038/nrclinonc.2010.139
80. Jones, C. H., Chen, C. K., Ravikrishnan, A., Rane, S., and Pfeifer, B. A. (2013). Overcoming nonviral gene delivery barriers: perspective and future. Mol. Pharm. 10, 4082-4098. doi: 10.1021/mp400467x
81. Kamen, B. A., and Smith, A. K. (2004). A review of folate receptor alpha cycling and 5-methyltetrahydrofolate accumulation with an emphasis on cell models in vitro. Adv. Drug Deliv. Rev. 56, 1085-1097. doi: 10.1016/j.addr.2004.01.002
82. Kawano, K., Watanabe, M., Yamamoto, T., Yokoyama, M., Opanasopit, P., Okano, T., et al. (2006). Enhanced antitumor effect of camptothecin loaded in long-circulating polymeric micelles. J. Control. Release 112, 329-332. doi: 10.1016/j.jconrel.2006.03.012
83. Keefe, A. D., Pai, S., and Ellington, A. (2010). Aptamers as therapeutics. Nat. Rev. Drug Discov. 9, 537-550. doi: 10.1038/nrd3141
84. Kheirolomoom, A., Mahakian, L. M., Lai, C. Y., Lindfors, H. A., Seo, J. W., Paoli, E. E., et al. (2010). Copper-doxorubicin as a nanoparticle cargo retains efficacy with minimal toxicity. Mol. Pharm. 7, 1948-1958. doi: 10.1021/mp100245u
85. Khemtong, C., Kessinger, C. W., Ren, J., Bey, E. A., Yang, S. G., Guthi, J. S., et al. (2009). In vivo off-resonance saturation magnetic resonance imaging of alphavbeta3-targeted superparamagnetic nanoparticles. Cancer Res. 69, 1651-1658. doi: 10.1158/0008-5472.CAN-08-3231
86. Kim, S. H., Jeong, J. H., Lee, S. H., Kim, S. W., and Park, T. G. (2008). Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer. J. Control. Release 129, 107-116. doi: 10.1016/j.jconrel.2008.03.008
87. Knop, K., Hoogenboom, R., Fischer, D., and Schubert, U. S. (2010). Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew. Chem. Int. Ed. Engl. 49, 6288-6308. doi: 10.1002/anie.200902672
88. Kresse, M., Wagner, S., Pfefferer, D., Lawaczeck, R., Elste, V., and Semmler, W. (1998). Targeting of ultrasmall superparamagnetic iron oxide (USPIO) particles to tumor cells in vivo by using transferrin receptor pathways. Magn. Reson. Med. 40, 236-242. doi: 10.1002/mrm.1910400209
89. Krogh-Madsen, M., Bender, B., Jensen, M. K., Nielsen, O. J., Friberg, L. E., and Honore, P. H. (2012). Population pharmacokinetics of cytarabine, etoposide, and daunorubicin in the treatment for acute myeloid leukemia. Cancer Chemother. Pharmacol. 69, 1155-1163. doi: 10.1007/s00280-011-1800-z
90. Kumar, M., Yigit, M., Dai, G. P., Moore, A., and Medarova, Z. (2010). Image-guided breast tumor therapy using a small interfering RNA nanodrug. Cancer Res. 70, 7553-7561. doi: 10.1158/0008-5472.CAN-10-2070
91. Kunjachan, S., Pola, R., Gremse, F., Theek, B., Ehling, J., Moeckel, D., et al. (2014). Passive versus active tumor targeting using RGD-and NGR-modified polymeric nanomedicines. Nano Lett. 14, 972-981. doi: 10.1021/nl404391r
92. Lasic, D. D., Frederik, P. M., Stuart, M. C., Barenholz, Y., and McIntosh, T. J. (1992). Gelation of liposome interior. A novel method for drug encapsulation. FEBS Lett. 312, 255-258. doi: 10.1016/0014-5793(92)80947-F
93. Le Garrec, D., Taillefer, J., Van Lier, J. E., Lenaerts, V., and Leroux, J. C. (2002). Optimizing pH-responsive polymeric micelles for drug delivery in a cancer photodynamic therapy model. J. Drug Target. 10, 429-437. doi: 10.1080/1061186021000001887
94. Libutti, S. K., Paciotti, G. F., Byrnes, A. A., Alexander, H. R., Gannon, W. E., Walker, M., et al. (2010). Phase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal Gold-rhTNF Nanomedicine. Clin. Cancer Res.16, 6139-6149. doi: 10.1158/1078-0432.CCR-10-0978
95. Liechty, W. B., and Peppas, N. A. (2012). Expert opinion: responsive polymer nanoparticles in cancer therapy. Eur. J. Pharm. Biopharm. 80, 241-246. doi: 10.1016/j.ejpb.2011.08.004
96. Liu, X. W., Tao, H. Q., Yang, K., Zhang, S. A., Lee, S. T., and Liu, Z. A. (2011). Optimization of surface chemistry on single-walled carbon nanotubes for in vivo photothermal ablation of tumors. Biomaterials 32, 144-151. doi: 10.1016/j.biomaterials.2010.08.096
97. Lorusso, P. M., Weiss, D., Guardino, E., Girish, S., and Sliwkowski, M. X. (2011). Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin. Cancer Res. 17, 6437-6447. doi: 10.1158/1078-0432.CCR-11-0762
98. Lowis, S., Lewis, I., Elsworth, A., Weston, C., Doz, F., Vassal, G., et al. (2006). A phase I study of intravenous liposomal daunorubicin (DaunoXome) in paediatric patients with relapsed or resistant solid tumours. Br. J. Cancer 95, 571-580. doi: 10.1038/sj.bjc.6603288
99. Lu, D., Burris, H. A., Wang, B., Dees, E. C., Cortes, J., Joshi, A., et al. (2012). Drug interaction potential of trastuzumab emtansine (T-DM1) combined with pertuzumab in patients with HER2-positive metastatic breast cancer. Curr. Drug Metab. 13, 911-922. doi: 10.2174/138920012802138688
100. Lu, W., Xiong, C., Zhang, G., Huang, Q., Zhang, R., Zhang, J. Z., et al. (2009). Targeted photothermal ablation of murine melanomas with melanocyte-stimulating hormone analog-conjugated hollow gold nanospheres. Clin. Cancer Res. 15, 876-886. doi: 10.1158/1078-0432.CCR-08-1480
101. Lu, W., Zhang, G., Zhang, R., Flores, L. G., Huang, Q., Gelovani, J. G., et al. (2010). Tumor site-specific silencing of NF-kappaB p65 by targeted hollow gold nanosphere-mediated photothermal transfection. Cancer Res. 70, 3177-3188. doi: 10.1158/0008-5472.CAN-09-3379
102. Lupold, S. E., Hicke, B. J., Lin, Y., and Coffey, D. S. (2002). Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res. 62, 4029-4033. doi: 10.1158/0008-5472.Can-12-2152
103. Lyass, O., Uziely, B., Ben-Yosef, R., Tzemach, D., Heshing, N. I., Lotem, M., et al. (2000). Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 89, 1037-1047. doi: 10.1002/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z
104. Mahakian, L. M., Farwell, D. G., Zhang, H., Seo, J. W., Poirier, B., Tinling, S. P., et al. (2014). Comparison of PET Imaging with Cu-64-Liposomes and F-18-FDG in the 7, 12-Dimethylbenz[a]anthracene (DMBA)-induced hamster buccal pouch model of oral dysplasia and squamous cell carcinoma. Mol. Imaging Biol. 16, 284-292. doi: 10.1007/s11307-013-0676-1
105. Medintz, I. L., Uyeda, H. T., Goldman, E. R., and Mattoussi, H. (2005). Quantum dot bioconjugates for imaging, labelling and sensing. Nat. Mater. 4, 435-446. doi: 10.1038/nmat1390
106. Melancon, M. P., Lu, W., Yang, Z., Zhang, R., Cheng, Z., Elliot, A. M., et al. (2008). In vitro and in vivo targeting of hollow gold nanoshells directed at epidermal growth factor receptor for photothermal ablation therapy. Mol. Cancer Ther. 7, 1730-1739. doi: 10.1158/1535-7163.MCT-08-0016
107. Michalet, X., Pinaud, F. F., Bentolila, L. A., Tsay, J. M., Doose, S., Li, J. J., et al. (2005). Quantum dots for live cells, in vivo imaging, and diagnostics. Science 307, 538-544. doi: 10.1126/science.1104274
108. Miele, E., Spinelli, G. P., Miele, E., Tomao, F., and Tomao, S. (2009). Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. Int. J. Nanomedicine 4, 99-105.
109. Miller, T., Breyer, S., Van Colen, G., Mier, W., Haberkorn, U., Geissler, S., et al. (2013). Premature drug release of polymeric micelles and its effects on tumor targeting. Int. J. Pharm. 445, 117-124. doi: 10.1016/j.ijpharm.2013.01.059
110. Mintzer, M. A., and Simanek, E. E. (2009). Nonviral vectors for gene delivery. Chem. Rev. 109, 259-302. doi: 10.1021/cr800409e
111. Morales-Avila, E., Ferro-Flores, G., Ocampo-Garcia, B. E., De Leon-Rodriguez, L. M., Santos-Cuevas, C. L., Garcia-Becerra, R., et al. (2011). Multimeric system of 99mTc-labeled gold nanoparticles conjugated to c[RGDfK(C)] for molecular imaging of tumor alpha(v)beta(3) expression. Bioconjug. Chem. 22, 913-922. doi: 10.1021/bc100551s
112. Mullard, A. (2013). Maturing antibody-drug conjugate pipeline hits 30. Nat. Rev. Drug Discov. 12, 329-332. doi: 10.1038/nrd4009
113. Muller, C., and Schibli, R. (2013). Prospects in folate receptor-targeted radionuclide therapy. Front. Oncol. 3:249. doi: 10.3389/fonc.2013.00249
114. Natarajan, A., Gruettner, C., Ivkov, R., Denardo, G. L., Mirick, G., Yuan, A., et al. (2008). NanoFerrite particle based radioimmunonanoparticles: binding affinity and in vivo pharmacokinetics. Bioconjug. Chem. 19, 1211-1218. doi: 10.1021/bc800015n
115. Naumann, R. W., Coleman, R. L., Burger, R. A., Sausville, E. A., Kutarska, E., Ghamande, S. A., et al. (2013). PRECEDENT: a randomized phase ii trial comparing vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. J. Clin. Oncol. 31, 4400-4406. doi: 10.1200/JCO.2013.49.7685
116. Nicolas, J., Mura, S., Brambilla, D., Mackiewicz, N., and Couvreur, P. (2013). Design, functionalization strategies and biomedical applications of targeted biodegradable/biocompatible polymer-based nanocarriers for drug delivery. Chem. Soc. Rev. 42, 1147-1235. doi: 10.1039/c2cs35265f
117. Niemeyer, C. M. (2001). Nanoparticles, proteins, and nucleic acids: biotechnology meets materials science. Angew. Chem. Int. Ed. Engl. 40, 4128-4158. doi: 10.1002/1521-3773(20011119)40:22<4128::AID-ANIE4128>3.0.CO;2-S
118. Novio, F., Simmchen, J., Vazquez-Mera, N., Amorin-Ferre, L., and Ruiz-Molina, D. (2013). Coordination polymer nanoparticles in medicine. Coord. Chem. Rev. 257, 2839-2847. doi: 10.1016/j.ccr.2013.04.022
119. Ohguchi, Y., Kawano, K., Hattori, Y., and Maitani, Y. (2008). Selective delivery of folate-PEG-linked, nanoemulsion-loaded aclacinomycin A to KB nasopharyngeal cells and xenograft: effect of chain length and amount of folate-PEG linker. J. Drug Target. 16, 660-667. doi: 10.1080/10611860802201464
120. Ohno, K., Mori, C., Akashi, T., Yoshida, S., Tago, Y., Tsujii, Y., et al. (2013). Fabrication of contrast agents for magnetic resonance imaging from polymer-brush-afforded iron oxide magnetic nanoparticles prepared by surface-initiated living radical polymerization. Biomacromolecules 14, 3453-3462. doi: 10.1021/bm400770n
121. Oyewumi, M. O., Yokel, R. A., Jay, M., Coakley, T., and Mumper, R. J. (2004). Comparison of cell uptake, biodistribution and tumor retention of folate-coated and PEG-coated gadolinium nanoparticles in tumor-bearing mice. J. Control. Release 95, 613-626. doi: 10.1016/j.jconrel.2004.01.002
122. Pack, D. W., Hoffman, A. S., Pun, S., and Stayton, P. S. (2005). Design and development of polymers for gene delivery. Nat. Rev. Drug Discov. 4, 581-593. doi: 10.1038/nrd1775
123. Paraskar, A., Soni, S., Roy, B., Papa, A. L., and Sengupta, S. (2012). Rationally designed oxaliplatin-nanoparticle for enhanced antitumor efficacy. Nanotechnology 23:075103. doi: 10.1088/0957-4484/23/7/075103
124. Park, J., Dvoracek, C., Lee, K. H., Galloway, J. F., Bhang, H. E. C., Pomper, M. G., et al. (2011). CuInSe/ZnS Core/Shell NIR quantum dots for biomedical imaging. Small 7, 3148-3152. doi: 10.1002/smll.201101558
125. Parker, N., Turk, M. J., Westrick, E., Lewis, J. D., Low, P. S., and Leamon, C. P. (2005). Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal. Biochem. 338, 284-293. doi: 10.1016/j.ab.2004.12.026
126. Penate Medina, O., Haikola, M., Tahtinen, M., Simpura, I., Kaukinen, S., Valtanen, H., et al. (2011). Liposomal tumor targeting in drug delivery utilizing MMP-2-and MMP-9-binding ligands. J. Drug Deliv. 2011, 160515. doi: 10.1155/2011/160515
127. Petersen, A. L., Binderup, T., Jolck, R. I., Rasmussen, P., Henriksen, J. R., Pfeifer, A. K., et al. (2012). Positron emission tomography evaluation of somatostatin receptor targeted 64Cu-TATE-liposomes in a human neuroendocrine carcinoma mouse model. J. Control. Release 160, 254-263. doi: 10.1016/j.jconrel.2011.12.038
128. Petryayeva, E., Algar, W. R., and Medintz, I. L. (2013). Quantum dots in bioanalysis: a review of applications across various platforms for fluorescence spectroscopy and imaging. Appl. Spectrosc. 67, 215-252. doi: 10.1366/12-06948
129. Piscitelli, S. C., Rodvold, K. A., Rushing, D. A., and Tewksbury, D. A. (1993). Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer. Clin. Pharmacol. Ther. 53, 555-561. doi: 10.1038/clpt.1993.69
130. Poon, Z., Lee, J. A., Huang, S., Prevost, R. J., and Hammond, P. T. (2011). Highly stable, ligand-clustered "patchy" micelle nanocarriers for systemic tumor targeting. Nanomedicine 7, 201-209. doi: 10.1016/j.nano.2010.07.008
131. Prato, M., Kostarelos, K., and Bianco, A. (2008). Functionalized carbon nanotubes in drug design and discovery. Acc. Chem. Res. 41, 60-68. doi: 10.1021/ar700089b
132. Puvanakrishnan, P., Park, J., Chatterjee, D., Krishnan, S., and Tunnell, J. W. (2012). In vivo tumor targeting of gold nanoparticles: effect of particle type and dosing strategy. Int. J. Nanomedicine 7, 1251-1258. doi: 10.2147/IJN.S29147
133. Reddy, L. H., Sharma, R. K., and Murthy, R. R. (2006). Enhanced delivery of etoposide to Dalton's lymphoma in mice through polysorbate 20 micelles. Acta Pharm. 56, 143-155.
134. Rijcken, C. J., Snel, C. J., Schiffelers, R. M., Van Nostrum, C. F., and Hennink, W. E. (2007). Hydrolysable core-crosslinked thermosensitive polymeric micelles: synthesis, characterisation and in vivo studies. Biomaterials 28, 5581-5593. doi: 10.1016/j.biomaterials.2007.08.047
135. Robinson, J. T., Hong, G. S., Liang, Y. Y., Zhang, B., Yaghi, O. K., and Dai, H. J. (2012). In vivo fluorescence imaging in the second near-infrared window with long circulating carbon nanotubes capable of ultrahigh tumor uptake. J. Am. Chem. Soc. 134, 10664-10669. doi: 10.1021/ja303737a
136. Rong, P. F., Yang, K., Srivastan, A., Kiesewetter, D. O., Yue, X. Y., Wang, F., et al. (2014). Photosensitizer loaded nano-graphene for multimodality imaging guided tumor photodynamic therapy. Theranostics 4, 229-239. doi: 10.7150/thno.8070
137. Rossin, R., Pan, D. P. J., Qi, K., Turner, J. L., Sun, X. K., Wooley, K. L., et al. (2005). Cu-64-labeled folate-conjugated shell cross-linked nanoparticles for tumor imaging and radiotherapy: synthesis, radiolabeling, and biologic evaluation. J. Nucl. Med. 46, 1210-1218.
138. Ruoslahti, E. (1996). RGD and other recognition sequences for integrins. Annu. Rev. Cell Dev. Biol. 12, 697-715. doi: 10.1146/annurev.cellbio.12.1.697
139. Sailor, M. J., and Park, J. H. (2012). Hybrid nanoparticles for detection and treatment of cancer. Adv. Mater. 24, 3779-3802. doi: 10.1002/adma.201200653
140. Sassoon, I., and Blanc, V. (2013). Antibody-drug conjugate (ADC) clinical pipeline: a review. Methods Mol. Biol. 1045, 1-27. doi: 10.1007/978-1-62703-541-5_1
141. Seynhaeve, A. L. B., Dicheva, B. M., Hoving, S., Koning, G. A., and Ten Hagen, T. L. M. (2013). Intact Doxil is taken up intracellularly and released doxorubicin sequesters in the lysosome: evaluated by In vitro/In vivo live cell imaging. J. Control. Release 172, 330-340. doi: 10.1016/j.jconrel.2013.08.034
142. Sheldrake, H. M., and Patterson, L. H. (2009). Function and antagonism of beta3 integrins in the development of cancer therapy. Curr. Cancer Drug Targets 9, 519-540. doi: 10.2174/156800909788486713
143. Shi, S. X., Yang, K., Hong, H., Valdovinos, H. F., Nayak, T. R., Zhang, Y., et al. (2013). Tumor vasculature targeting and imaging in living mice with reduced graphene oxide. Biomaterials 34, 3002-3009. doi: 10.1016/j.biomaterials.2013.01.047
144. Shiraishi, K., Kawano, K., Minowa, T., Maitani, Y., and Yokoyama, M. (2009). Preparation and in vivo imaging of PEG-poly(L-lysine)-based polymeric micelle MRI contrast agents. J. Control. Release 136, 14-20. doi: 10.1016/j.jconrel.2009.01.010
145. Sievers, E. L., and Senter, P. D. (2013). Antibody-drug conjugates in cancer therapy. Annu. Rev. Med. 64, 15-29. doi: 10.1146/annurev-med-050311-201823
146. Silverman, J. A., and Deitcher, S. R. (2013). Marqibo(R) (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine. Cancer Chemother. Pharmacol. 71, 555-564. doi: 10.1007/s00280-012-2042-4
147. Soundararajan, A., Bao, A., Phillips, W. T., Perez, R., and Goins, B. A. (2009). [Re-186]Liposomal doxorubicin (Doxil): in vitro stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft model. Nucl. Med. Biol. 36, 515-524. doi: 10.1016/j.nucmedbio.2009.02.004
148. Sparreboom, A., Scripture, C. D., Trieu, V., Williams, P. J., De, T., Yang, A., et al. (2005). Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin. Cancer Res. 11, 4136-4143. doi: 10.1158/1078-0432.CCR-04-2291
149. Steichen, S. D., Caldorera-Moore, M., and Peppas, N. A. (2012). A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics. Eur. J. Pharm. Sci. 48, 416-427. doi: 10.1016/j.ejps.2012.12.006
150. Steinmetz, N. F. (2010). Viral nanoparticles as platforms for next-generation therapeutics and imaging devices. Nanomed. Nanotechnol. Biol. Med. 6, 634-641. doi: 10.1016/j.nano.2010.04.005
151. Sumitani, S., Oishi, M., and Nagasaki, Y. (2011). Carborane confined nanoparticles for boron neutron capture therapy: improved stability, blood circulation time and tumor accumulation. React. Funct. Polym. 71, 684-693. doi: 10.1016/j.reactfunctpolym.2011.03.010
152. Sun, X. L., Huang, X. L., Guo, J. X., Zhu, W. L., Ding, Y., Niu, G., et al. (2014). Self-illuminating Cu-64-Doped CdSe/ZnS nanocrystals for in vivo tumor Imaging. J. Am. Chem. Soc. 136, 1706-1709. doi: 10.1021/ja410438n
153. Tang, L., Yang, X. J., Dobrucki, L. W., Chaudhury, I., Yin, Q., Yao, C., et al. (2012). Aptamer-functionalized, ultra-small, monodisperse silica nanoconjugates for targeted dual-modal imaging of lymph nodes with metastatic tumors. Angew. Chem. Int. Ed. Engl. 51, 12721-12726. doi: 10.1002/anie.201205271
154. Tinkov, S., Winter, G., Coester, C., and Bekeredjian, R. (2010). New doxorubicin-loaded phospholipid microbubbles for targeted tumor therapy: part I-Formulation development and in-vitro characterization. J. Control. Release 143, 143-150. doi: 10.1016/j.jconrel.2009.12.026
155. Torchilin, V. (2011). Tumor delivery of macromolecular drugs based on the EPR effect. Adv. Drug Deliv. Rev. 63, 131-135. doi: 10.1016/j.addr.2010.03.011
156. Tuerk, C., and Gold, L. (1990). Systematic evolution of ligands by exponential enrichment-RNA ligands to bacteriophage-t4 DNA-polymerase. Science 249, 505-510. doi: 10.1126/science.2200121
157. Turk, M. J., Waters, D. J., and Low, P. S. (2004). Folate-conjugated liposomes preferentially target macrophages associated with ovarian carcinoma. Cancer Lett. 213, 165-172. doi: 10.1016/j.canlet.2003.12.028
158. Ujiie, K., Kanayama, N., Asai, K., Kishimoto, M., Ohara, Y., Akashi, Y., et al. (2011). Preparation of highly dispersible and tumor-accumulative, iron oxide nanoparticles Multi-point anchoring of PEG-b-poly(4-vinylbenzylphosphonate) improves performance significantly. Colloids Surf. B Biointerfaces 88, 771-778. doi: 10.1016/j.colsurfb.2011.08.013
159. Vanblaaderen, A., and Vrij, A. (1992). Synthesis and characterization of colloidal dispersions of fluorescent, monodisperse silica spheres. Langmuir 8, 2921-2931. doi: 10.1021/la00048a013
160. Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., et al. (2012). Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 367, 1783-1791. doi: 10.1056/NEJMoa1209124
161. Vllasaliu, D., Fowler, R., and Stolnik, S. (2014). PEGylated nanomedicines: recent progress and remaining concerns. Expert Opin. Drug Deliv. 11, 139-154. doi: 10.1517/17425247.2014.866651
162. Von Maltzahn, G., Park, J. H., Agrawal, A., Bandaru, N. K., Das, S. K., Sailor, M. J., et al. (2009). Computationally guided photothermal tumor therapy using long-circulating gold nanorod antennas. Cancer Res. 69, 3892-3900. doi: 10.1158/0008-5472.CAN-08-4242
163. Walkey, C. D., and Chan, W. C. W. (2012). Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment. Chem. Soc. Rev. 41, 2780-2799. doi: 10.1039/c1cs15233e
164. Wang, H. E., Yu, H. M., Lu, Y. C., Heish, N. N., Tseng, Y. L., Huang, K. L., et al. (2006). Internal radiotherapy and dosimetric study for In-111/Lu-177-pegylated liposomes conjugates in tumor-bearing mice. Nucl. Instrum. Methods Phys. Res. Sec. A. 569, 533-537. doi: 10.1016/j.nima.2006.08.124
165. Wang, M., and Gartel, A. L. (2011). Micelle-encapsulated thiostrepton as an effective nanomedicine for inhibiting tumor growth and for suppressing FOXM1 in human xenografts. Mol. Cancer Ther. 10, 2287-2297. doi: 10.1158/1535-7163.MCT-11-0536
166. Weissleder, R., Kelly, K., Sun, E. Y., Shtatland, T., and Josephson, L. (2005). Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat. Biotechnol. 23, 1418-1423. doi: 10.1038/nbt1159
167. Xiao, Y. L., Hong, H., Javadi, A., Engle, J. W., Xu, W. J., Yang, Y. A., et al. (2012). Multifunctional unimolecular micelles for cancer-targeted drug delivery and positron emission tomography imaging. Biomaterials 33, 3071-3082. doi: 10.1016/j.biomaterials.2011.12.030
168. Yang, K., Hu, L. L., Ma, X. X., Ye, S. Q., Cheng, L., Shi, X. Z., et al. (2012). Multimodal imaging guided photothermal therapy using functionalized graphene nanosheets anchored with magnetic nanoparticles. Adv. Mater. 24, 1868-1872. doi: 10.1002/adma.201104964
169. Yang, X., Hong, H., Grailer, J. J., Rowland, I. J., Javadi, A., Hurley, S. A., et al. (2011). cRGD-functionalized, DOX-conjugated, and (6)(4)Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging. Biomaterials 32, 4151-4160. doi: 10.1016/j.biomaterials.2011.02.006
170. Yardley, D. A. (2013). nab-Paclitaxel mechanisms of action and delivery. J. Control. Release 170, 365-372. doi: 10.1016/j.jconrel.2013.05.041
171. Yokoyama, M., Okano, T., Sakurai, Y., Fukushima, S., Okamoto, K., and Kataoka, K. (1999). Selective delivery of adiramycin to a solid tumor using a polymeric micelle carrier system. J. Drug Target. 7, 171-186. doi: 10.3109/10611869909085500
172. Younes, A., Bartlett, N. L., Leonard, J. P., Kennedy, D. A., Lynch, C. M., Sievers, E. L., et al. (2010). Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N. Engl. J. Med. 363, 1812-1821. doi: 10.1056/NEJMoa1002965
173. Yu, B., Mao, Y., Bai, L. Y., Herman, S. E., Wang, X., Ramanunni, A., et al. (2013). Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia. Blood 121, 136-147. doi: 10.1182/blood-2012-01-407742
174. Zhan, C., Gu, B., Xie, C., Li, J., Liu, Y., and Lu, W. (2010). Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect. J. Control. Release 143, 136-142. doi: 10.1016/j.jconrel.2009.12.020
175. Zhang, R., Lu, W., Wen, X., Huang, M., Zhou, M., Liang, D., et al. (2011a). Annexin A5-conjugated polymeric micelles for dual SPECT and optical detection of apoptosis. J. Nucl. Med. 52, 958-964. doi: 10.2967/jnumed.110.083220
176. Zhang, R., Xiong, C., Huang, M., Zhou, M., Huang, Q., Wen, X., et al. (2011b). Peptide-conjugated polymeric micellar nanoparticles for Dual SPECT and optical imaging of EphB4 receptors in prostate cancer xenografts. Biomaterials 32, 5872-5879. doi: 10.1016/j.biomaterials.2011.04.070
177. Zhang, Y., Satterlee, A., and Huang, L. (2012). In vivo gene delivery by nonviral vectors: overcoming hurdles? Mol. Ther.20, 1298-1304. doi: 10.1038/mt.2012.79
178. Zhao, J., Song, S. L., Zhong, M., and Li, C. (2012). Dual-modal tumor imaging via long-circulating biodegradable core-cross-linked polymeric micelles. ACS Macro Lett. 1, 150-153. doi: 10.1021/mz200034f
179. Zheng, J., Jaffray, D., and Allien, C. (2009). Quantitative CT imaging of the spatial and temporal distribution of liposomes in a rabbit tumor model. Mol. Pharm. 6, 571-580. doi: 10.1021/mp800234r
180. Zhu, H., Zhao, J., Lin, X. F., Hong, Y., Li, C., and Yang, Z. (2013). Design, synthesis and evaluation of dual-modality glyco-nanoparticles for tumor imaging. Molecules 18, 6425-6438. doi: 10.3390/molecules18066425